WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005118638) DEGRADATION-RESISTANT ANALOGUES OF PRO-INSULIN C-PEPTIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/118638    International Application No.:    PCT/GB2005/002168
Publication Date: 15.12.2005 International Filing Date: 01.06.2005
Chapter 2 Demand Filed:    31.03.2006    
IPC:
C07K 14/62 (2006.01)
Applicants: CREATIVE PEPTIDES SWEDEN AB [SE/SE]; Gavlegatan 22, S-113 85 Stockholm (SE) (For All Designated States Except US).
DZIEGLEWSKA, Hanna, Eva [GB/GB]; (GB) (SC only).
WAHREN, John [SE/SE]; (SE) (For US Only).
JÖRNVALL, Hans [SE/SE]; (SE) (For US Only).
MELLES, Ermias [SE/SE]; (SE) (For US Only)
Inventors: WAHREN, John; (SE).
JÖRNVALL, Hans; (SE).
MELLES, Ermias; (SE)
Agent: FRANK B. DEHN & CO.; St Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB)
Priority Data:
0412174.5 01.06.2004 GB
Title (EN) DEGRADATION-RESISTANT ANALOGUES OF PRO-INSULIN C-PEPTIDE
(FR) ANALOGUES DU PEPTIDE C PROINSULINE RESISTANTS A LA DEGRADATION
Abstract: front page image
(EN)The present invention provides a C-peptide analogue wherein the C-peptide is modified at one or more leucine and/or one or more valine residues, and wherein the analogue has an increased resistance to proteolytic degradation as compared to un-modified C-peptide. Such analogues may be used in C-peptide therapy, notably in the therapy of diabetes and/or diabetic complications.
(FR)L'invention concerne un analogue du peptide C. Selon l'invention, le peptide C est modifié au niveau d'au moins un résidu leucine et/ou au moins un résidu valine, et l'analogue présente une résistance à la dégradation protéolytique supérieure à celle d'un peptide C non modifié. Les analogues selon l'invention peuvent être utilisés dans un traitement à base de peptide C, notamment dans le traitement du diabète et/ou des complications liées au diabète.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)